To verify these results, we established a syngeneic tumor model, which revealed that the SGLT2 inhibitor or SGLT2 silencing both significantly inhibited the tumor growth (Fig. 3e) and significantly increased the number of infiltrated immune cells, including CD4+ and CD8+ lymphocyte cells (Fig. 3f, g and Supplementary Fig. 2a). This evidence concerns the gene SLC5A2 and neoplasm.